Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis

International Journal of Antimicrobial Agents

Volumn 46, Issue 3, 2015, Pages 242-248

  Raz Pasteur, Ayelet ^a   Shasha, David ^b   Paul, Mical ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Division of Infectious Diseases   (Israel)

Author keywords

Community acquired pneumonia; Macrolides; Meta analysis; Quinolones; Review; Systematic

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOPERAZONE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; ANTIINFECTIVE AGENT; BETA LACTAM; QUINOLONE DERIVATIVE;

COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HOSPITAL PATIENT; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; COMBINATION DRUG THERAPY; COMMUNITY-ACQUIRED INFECTIONS; COMPARATIVE STUDY; PNEUMONIA, BACTERIAL; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FLUOROQUINOLONES; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84940446806     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.04.010     Document Type: Review

References (29)

1. L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, N.C. Dean, and et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 2007 S27 S72
2. W.S. Lim, S.V. Baudouin, R.C. George, A.T. Hill, C. Jamieson, I. Le Jeune, and et al. Pneumonia guidelines committee of the BTS standards of care committee BTS guidelines for the management of community acquired pneumonia in adults: update 2009 Thorax 64 2009 iii1 iii55
3. J. Ruhe, and D. Mildvan Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward? Infect Dis Clin N Am 27 2013 115 132
4. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions. Version 5.1.0 2011 The Cochrane Collaboration Chichester, UK 〈http://www.cochrane-handbook.org〉. [updated March 2011, accessed 21.05.15]
5. D.F. Postma, C.H. van Werkhoven, L.J. van Elden, S.F. Thijsen, A.I. Hoepelman, J.A. Kluytmans, and et al. Antibiotic treatment strategies for community-acquired pneumonia in adults N Engl J Med 372 2015 1312 1323
6. A. Etemadi, A. Ardeshirzadeh, M. Maaleki, A. Chenaneh, and S. Ahmadi Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Eur Respir J 38 2011 2558
7. E. Frank, J. Liu, G. Kinasewitz, G.J. Moran, M.P. Oross, W.H. Olson, and et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia Clin Ther 24 2002 1292 1308
8. J.H. Lee, S.W. Kim, J.H. Kim, Y.J. Ryu, and J.H. Chang High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study Clin Drug Investig 32 2012 569 576
9. O. Leroy, P. Saux, J.P. Bedos, and E. Caulin Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors Chest 128 2005 172 183
10. T.Y. Lin, S.M. Lin, H.C. Chen, C.J. Wang, Y.M. Wang, M.L. Chang, and et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia Chang Gung Med J 30 2007 321 332
11. H. Portier, C. Brambilla, M. Garre, F. Paganin, P. Poubeau, and P. Zuck Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors Eur J Clin Microbiol Infect Dis 24 2005 367 376
12. H. Portier, T. May, and A. Proust Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French study group J Antimicrob Chemother 37 1996 83 91
13. J. Ramirez, and T. File No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Proceedings of the European Respiratory Society 13th Annual Congress 27 September-1 October 2003; Vienna, Austria European Respiratory Society [abstract P2120]
14. A. Torres, J. Garau, P. Arvis, J. Carlet, S. Choudhri, A. Kureishi, and et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial Clin Infect Dis 46 2008 1499 1509
15. E.N. Vergis, A. Indorf, T.M. File Jr. , J. Phillips, J. Bates, J. Tan, and et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial Arch Intern Med 160 2000 1294 1300
16. S. Xu, S. Xiong, Y. Xu, J. Liu, H. Liu, J. Zhao, and et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia J Huazhong Univ Sci Technol Med Sci 26 2006 421 424
17. M. Zervos, L.A. Mandell, P.S. Vrooman, C.P. Andrews, A. McIvor, R.H. Abdulla, and et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia Treat Respir Med 3 2004 329 336
18. C. Fogarty, G. Siami, R. Kohler, T.M. File Jr. , A.M. Tennenberg, W.H. Olson, and et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults Clin Infect Dis 38 2004 S16 S23
19. E. Rovira, E. Martinez-Moragon, A. Belda, F. Gonzalvo, F. Ripolles, and J.M. Pascual Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime Respiration 66 1999 413 418
20. N. Vetter, D. Stamler, S. O'Neill, P. Rafferty, G. Praz, J.D. Cantolla, and et al. Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalised community-acquired pneumonia patients - intravenous followed by oral therapy Clin Drug Investig 14 1997 439 449
21. K.Z. Vardakas, I.I. Siempos, A. Grammatikos, Z. Athanassa, I.P. Korbila, and M.E. Falagas Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials CMAJ 179 2008 1269 1277
22. K. Skalsky, D. Yahav, A. Lador, N. Eliakim-Raz, L. Leibovici, and M. Paul Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials Clin Microbiol Infect 19 2013 370 378
23. L. Asadi, W.I. Sligl, D.T. Eurich, I.N. Colmers, L. Tjosvold, T.J. Marrie, and et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis Clin Infect Dis 55 2012 371 380
24. N. Garin, D. Genne, S. Carballo, C. Chuard, G. Eich, O. Hugli, and et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial JAMA Intern Med 174 2014 1894 1901
25. N. Eliakim-Raz, E. Robenshtok, D. Shefet, A. Gafter-Gvili, L. Vidal, M. Paul, and et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults Cochrane Database Syst Rev 9 2012 CD004418
26. J.P. Donnelly, J.W. Baddley, and H.E. Wang Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments Antimicrob Agents Chemother 58 2014 1451 1457
27. M. Lafaurie, R. Porcher, J.L. Donay, S. Touratier, and J.M. Molina Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study J Antimicrob Chemother 67 2012 1010 1015
28. S.N. Patel, A. McGeer, R. Melano, G.J. Tyrrell, K. Green, D.R. Pillai, and et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada Antimicrob Agents Chemother 55 2011 3703 3708
29. J. Bennett, R. Dolin, and M. Blaser Mandell, Douglas, and Bennett's principles and practice of infectious diseases 8th ed. 2015 Elsevier Philadelphia, PA